Is chronic inhibition of phosphodiesterase type 5 cardioprotective and safe? A meta-analysis of randomized controlled trials

BACKGROUND: The myocardial effects of phosphodiesterase type 5 inhibitors (PDE5i) have recently received consideration in several preclinical studies. The risk/benefit ratio in humans remains unclear. METHODS: We performed a meta-analysis of randomized, placebo-controlled trials (RCTs) to evaluate t...

Descripción completa

Detalles Bibliográficos
Autores principales: Giannetta, Elisa, Feola, Tiziana, Gianfrilli, Daniele, Pofi, Riccardo, Dall’Armi, Valentina, Badagliacca, Roberto, Barbagallo, Federica, Lenzi, Andrea, Isidori, Andrea M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4201993/
https://www.ncbi.nlm.nih.gov/pubmed/25330139
http://dx.doi.org/10.1186/s12916-014-0185-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4201993/
https://www.ncbi.nlm.nih.gov/pubmed/25330139
http://dx.doi.org/10.1186/s12916-014-0185-3

Ejemplares similares